Physician profile
Michael E Klufas
NPI 1205822277
$37,150.53
in general payments reported to CMS, 2019-2025
75 companies · $4,672 in 2025
The $4,672 reported for 2025 was more than what 97% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,745 · 2020: $3,559 · 2021: $7,550 · 2022: $5,579 · 2023: $6,503 · 2024: $5,541 · 2025: $4,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,516.84 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $4,175.72 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $3,130.10 | 2019-2024 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $3,085.63 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Pfizer INC. | $3,054.93 | 2019-2025 | |
| Amgen INC. | $2,263.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,766.21 | 2020-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,653.31 | 2019-2025 | Jardiance, Spiriva Respimat, Tradjenta |
| Abbvie INC. | $1,497.27 | 2020-2025 | |
| Abbott Laboratories | $1,173.56 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $1,164.90 | 2023-2025 | Rexulti, Nuedexta |
| Neurocrine Biosciences, INC. | $846.12 | 2022-2025 | Ingrezza, Ongentys |
| Avanir Pharmaceuticals, INC. | $837.86 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $797.15 | 2022-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $716.97 | 2019-2025 | Eliquis, Camzyos |
| Lilly USA, LLC | $712.71 | 2020-2025 | Mounjaro, Jardiance, Kisunla |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Klufas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.